The pharmaceutical treatment of metabolic diseases has become a crucial technique [45], including agents such as insulin sensitizers, lipase inhibitors, xanthine oxidase inhibitors, and farnesoid X receptor (FXR) agonists. This evidence concerns the gene NR1H4 and metabolic disease.